Introduction: Although, thalidomide has been shown to be effective in patients with refractory cutaneous lupus erythematosus (CLE), its use is still hampered by its potential severe side effects and the current restricted availability. The aim of this observational study is to prospectively evaluate the clinical efficacy and safety of low-dose thalidomide and to establish prognostic factors of clinical outcome.
Methods: Sixty consecutive patients with refractory CLE were treated with thalidomide (100 mg/day). Clinical response was assessed by the CLE disease area and severity index (CLASI). Clinical and immunological parameters were evaluated ...
Thalidomide in the treatment of refractory cutaneous lupus: prognostic factors of clinical outcome is a post from: Skincare
Thalidomide in the treatment of refractory cutaneous lupus: prognostic factors of clinical outcome via BuzzBlazer.com
No comments:
Post a Comment